{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Head+and+Neck+Squamous+Cell+Carcinoma&page=3",
    "query": {
      "condition": "Resectable Head and Neck Squamous Cell Carcinoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 63,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Head+and+Neck+Squamous+Cell+Carcinoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Head+and+Neck+Squamous+Cell+Carcinoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T14:55:33.592Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05120947",
      "title": "Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Resectable Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "42 Gy Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "39 Gy Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "32.5 Gy Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2021-12-01",
      "completion_date": "2025-11-22",
      "has_results": true,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05120947"
    },
    {
      "nct_id": "NCT06568172",
      "title": "Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eyelid Squamous Cell Carcinoma",
        "Recurrent Eyelid Squamous Cell Carcinoma",
        "Recurrent Skin Acantholytic Squamous Cell Carcinoma",
        "Recurrent Skin Clear Cell Squamous Cell Carcinoma",
        "Recurrent Skin Lymphoepithelial Carcinoma",
        "Recurrent Skin Spindle Cell Squamous Cell Carcinoma",
        "Recurrent Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation",
        "Resectable Eyelid Squamous Cell Carcinoma",
        "Resectable Skin Acantholytic Squamous Cell Carcinoma",
        "Resectable Skin Clear Cell Squamous Cell Carcinoma",
        "Resectable Skin Lymphoepithelial Carcinoma",
        "Resectable Skin Spindle Cell Squamous Cell Carcinoma",
        "Resectable Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation",
        "Skin Acantholytic Squamous Cell Carcinoma",
        "Skin Clear Cell Squamous Cell Carcinoma",
        "Skin Lymphoepithelial Carcinoma",
        "Skin Spindle Cell Squamous Cell Carcinoma",
        "Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cemiplimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Image Guided Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2025-02-18",
      "completion_date": "2031-08-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 196,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 147 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06568172"
    },
    {
      "nct_id": "NCT01553851",
      "title": "GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Oral",
        "Mouth Neoplasms"
      ],
      "interventions": [
        {
          "name": "GSK1120212",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-02",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-12-26",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01553851"
    },
    {
      "nct_id": "NCT00470496",
      "title": "Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Metastatic Squamous Neck Cancer With Occult Primary",
        "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Hypopharynx",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Recurrent Thyroid Cancer",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage I Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage I Basal Cell Carcinoma of the Lip",
        "Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Follicular Thyroid Cancer",
        "Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Lymphoepithelioma of the Nasopharynx",
        "Stage I Lymphoepithelioma of the Oropharynx",
        "Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage I Papillary Thyroid Cancer",
        "Stage I Salivary Gland Cancer",
        "Stage I Squamous Cell Carcinoma of the Hypopharynx",
        "Stage I Squamous Cell Carcinoma of the Larynx",
        "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage I Squamous Cell Carcinoma of the Oropharynx",
        "Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage I Verrucous Carcinoma of the Larynx",
        "Stage I Verrucous Carcinoma of the Oral Cavity",
        "Stage II Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage II Basal Cell Carcinoma of the Lip",
        "Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity",
        "Stage II Follicular Thyroid Cancer",
        "Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity",
        "Stage II Lymphoepithelioma of the Nasopharynx",
        "Stage II Lymphoepithelioma of the Oropharynx",
        "Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity",
        "Stage II Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage II Papillary Thyroid Cancer",
        "Stage II Salivary Gland Cancer",
        "Stage II Squamous Cell Carcinoma of the Hypopharynx",
        "Stage II Squamous Cell Carcinoma of the Larynx",
        "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage II Squamous Cell Carcinoma of the Oropharynx",
        "Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity",
        "Stage II Verrucous Carcinoma of the Larynx",
        "Stage II Verrucous Carcinoma of the Oral Cavity"
      ],
      "interventions": [
        {
          "name": "HPPH",
          "type": "DRUG"
        },
        {
          "name": "photodynamic therapy",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2006-10-19",
      "completion_date": "2018-08-30",
      "has_results": false,
      "last_update_posted_date": "2022-07-25",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00470496"
    },
    {
      "nct_id": "NCT04630353",
      "title": "A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "HB-201 IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-07-21",
      "completion_date": "2023-11-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04630353"
    },
    {
      "nct_id": "NCT02544880",
      "title": "PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "Tadalafil",
          "type": "DRUG"
        },
        {
          "name": "Anti-MUC1 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tadalafil Placebo",
          "type": "OTHER"
        },
        {
          "name": "Anti-MUC1 Vaccine Placebo",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care Treatment",
          "type": "OTHER"
        },
        {
          "name": "Anti-Influenza Vaccine Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Donald T. Weed, MD, FACS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2016-04-25",
      "completion_date": "2021-06-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-15",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02544880"
    },
    {
      "nct_id": "NCT06162377",
      "title": "Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A \"Window of Opportunity\" Pilot Study.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Methylnaltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-01-10",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162377"
    },
    {
      "nct_id": "NCT06161545",
      "title": "Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage II Squamous Cell Carcinoma of the Head and Neck",
        "Stage III Squamous Cell Carcinoma of the Head and Neck",
        "Stage IV Squamous Cell Carcinoma of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "PD-L1 t-haNK cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-09-24",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161545"
    },
    {
      "nct_id": "NCT03342911",
      "title": "Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
        "Stage II Oropharyngeal Squamous Cell Carcinoma",
        "Stage III Hypopharyngeal Squamous Cell Carcinoma",
        "Stage III Laryngeal Squamous Cell Carcinoma",
        "Stage III Oral Cavity Squamous Cell Carcinoma",
        "Stage III Oropharyngeal Squamous Cell Carcinoma",
        "Stage IV Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IV Laryngeal Squamous Cell Carcinoma",
        "Stage IV Oral Cavity Squamous Cell Carcinoma",
        "Stage IV Oropharyngeal Squamous Cell Carcinoma",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IVA Laryngeal Squamous Cell Carcinoma",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma",
        "Stage IVB Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IVB Laryngeal Squamous Cell Carcinoma",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma",
        "Stage IVC Hypopharyngeal Squamous Cell Carcinoma",
        "Stage IVC Laryngeal Squamous Cell Carcinoma",
        "Stage IVC Oral Cavity Squamous Cell Carcinoma",
        "Stage IVC Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-11-13",
      "completion_date": "2020-10-06",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 3,
      "location_summary": "Abington, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Abington",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03342911"
    },
    {
      "nct_id": "NCT04588038",
      "title": "NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Resectable Oropharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Efineptakin alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hyunseok Kang, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-03-12",
      "completion_date": "2025-02-03",
      "has_results": false,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-06T14:55:33.592Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04588038"
    }
  ]
}